Full Text View
Tabular View
No Study Results Posted
Related Studies
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Semafore Pharmaceuticals.
Recruitment status was  Recruiting
Study NCT00907205   Information provided by Semafore Pharmaceuticals

First Received on May 20, 2009.   Last Updated on May 21, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced or Metastatic Solid Tumors
Cancer
Solid Cancers
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
SF1126
Sponsors listed in this trial
Semafore Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services